View Older Stories View More Recent Stories

Feb 8, 2017 10:54AM Bristol-Myers Squibb to Take Part in Leerink 6th Annual Global Health Care Conference
Feb 2, 2017 04:41PM Bristol-Myers Squibb (BMY) Confirms FDA Approval for Opdivo in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Feb 2, 2017 04:15PM Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Feb 2, 2017 09:21AM Cancer Survivors Need More Efficient Integrated Long-Term Care and Stronger Policies Across Healthcare, Advocacy and the Workplace, New Research Concludes
Feb 1, 2017 12:22PM Bristol-Myers Squibb (BMY) Says EPO Upheld Decision That Found '038 Patent Invalid
Feb 1, 2017 12:19PM Bristol-Myers Squibb Announces European Patent Office Decision on Sprycel
Jan 26, 2017 06:59AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results
Jan 20, 2017 04:02PM Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 04:01PM Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and License Agreement with Merck to Resolve PD-1 Antibody Patent Litigation
Jan 20, 2017 07:24AM Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
Jan 19, 2017 06:30PM Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Jan 19, 2017 09:00AM Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study
Jan 6, 2017 07:05AM Bristol-Myers Squibb (BMY) Announces Biomarker Research Collaboration with GeneCentric Diagnostics
Jan 6, 2017 06:59AM Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration
Jan 5, 2017 07:05AM Bristol-Myers Squibb (BMY) Enters Collaboration with JNJ's (JNJ) Janssen for Opdivo/Darzalex Combo
Jan 5, 2017 06:59AM Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combination with Darzalex (daratumumab)
Jan 3, 2017 09:18AM Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Dec 29, 2016 09:00AM Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
Dec 21, 2016 08:30AM Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
Dec 21, 2016 07:01AM Bristol-Myers Squibb (BMY) and Calithera Biosciences (CALA) Enter Pact to Evaluate Opdivo in Combination with CB-839 in ccRCC
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Dec 21, 2016 06:59AM Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
Dec 20, 2016 07:00AM Bristol-Myers Squibb (BMY) Licenses 'Armed' Oncolytic Virus NG-348 from PsiOxus Therapeutics
Dec 20, 2016 06:59AM Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors
Dec 19, 2016 08:04AM Portola Pharma (PTLA) Enters $50M Loan Agreement with Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Continue AndexXa Development
Dec 19, 2016 08:00AM Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)
Dec 13, 2016 09:30AM Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint
Dec 9, 2016 04:00PM Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
Dec 8, 2016 04:15PM Bristol-Myers Squibb Announces Dividend Increase
Dec 6, 2016 08:48AM Bristol-Myers Squibb (BMY) Opdivo Showed Encouraging Response and Survival Rates in SCLC Alone or Combined With Yervoy
Dec 6, 2016 08:45AM Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032
Dec 6, 2016 06:18AM Seattle Genetics (SGEN), Bristol-Myers (BMY) Present First Data from ADCETRIS + Opdivo Phase 1/2 in r/r HL
Dec 5, 2016 07:30PM Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin
Dec 5, 2016 06:07AM Bristol-Myers Squibb (BMY) Announces Positive Updated Opdivo Combo Phase 1b Data in NDCLC
Dec 5, 2016 05:00AM Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advanced Non-small Cell Lung Cancer, in Updated Phase 1b CheckMate -012 Study
Nov 30, 2016 09:54AM Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
Nov 22, 2016 03:02PM Bristol-Myers Squibb (BMY) Announces EC Approval for Opdivo to Treat Relapsed or Refractory Classical Hodgkin Lymphoma
Nov 22, 2016 03:00PM European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplan
Nov 22, 2016 08:04AM QuintilesIMS (Q) Enters anti-Cancer Treatment Collaborations with Leading Pharma Companies (PFE) (BMY)
Nov 16, 2016 05:14PM Bristol-Myers Squibb (BMY) Presents New Opdivo + Yervoy Data at IASLC 17th WCLC
Nov 16, 2016 05:13PM Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadership in Broad Lung Development Program
Nov 16, 2016 06:25AM Bristol-Myers Squibb (BMY), Enterome Enter Immuno-Oncology Collaboration for Microbiome-Derived Biomarkers Development
Nov 16, 2016 04:04AM Bristol-Myers Squibb and Enterome SA Announce Immuno-Oncology Collaboration Focused on Microbiome-derived Biomarkers, Drug Targets and Bioactive Molecules
Nov 16, 2016 03:00AM Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
Nov 14, 2016 07:10AM Bristol-Myers Squibb (BMY) Announces Additional CheckMate-032 Phase 1/2 Data in Previously Treated mUC Patients
Nov 14, 2016 06:59AM Bristol-Myers Squibb Showcases Rheumatoid Arthritis and Immunoscience Commitment with Depth of Research at 2016 American College of Rheumatology and Association of Rheumatology Health Professionals An
Nov 14, 2016 06:26AM Bristol-Myers Squibb (BMY), Innate Pharma SA Announce Encouraging Data from lirilumab and Opdivo Phase 1/2 in SCCHN Cohort
Nov 13, 2016 09:08AM Bristol-Myers Squibb (BMY) Announces Encouraging Data from Urelumab + Opdivo Phase 1/2 in Melanoma
Nov 12, 2016 11:30AM Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer
Nov 12, 2016 11:18AM Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (Nivolumab)
View More Recent Stories View Older Stories